Drugs / Mavorixafor
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Xolremdi | — | 2026-04-27 | europa.eu ↗ |
| Approved | US (FDA) | XOLREMDI | — | 2024-04-26 | fda.gov ↗ |
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT06858696 | Feb 2025 → Jan 2026 | liver disorder | X4 Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06914869 | Feb → May 2025 | — | X4 Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04274738 | Apr 2020 → Oct 2022 | Waldenstrom macroglobulinemia | X4 Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02823405 | Sep 2016 → Mar 2018 | melanoma | X4 Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02680782 | Jan → Feb 2016 | — | X4 Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT00361101 | Oct 2005 → Aug 2006 | HIV infectious disease | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00063804 | ? → Oct 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT04154488 | Oct 2021 → Aug 2024 | neutropenia | X4 Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT05103917 | Jul 2021 → Nov 2022 | triple-negative breast carcinoma | Abbisko Therapeutics Co, Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT02923531 | Dec 2016 → Aug 2018 | clear cell renal carcinoma | X4 Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT02667886 | Apr 2016 → Apr 2022 | clear cell renal carcinoma | X4 Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00089466 | Nov 2004 → Jun 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03005327 | Dec 2016 → Jun 2022 | WHIM syndrome | X4 Pharmaceuticals | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06056297 | Jun 2024 → Sep 2027 expected | neutropenia | X4 Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT03995108 | Oct 2019 → Dec 2025 | WHIM syndrome | X4 Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mavorixafor | “Mavorixafor is an oral small molecule selective antagonist of the CXCR4 receptor that increases mobilization and trafficking of white blood cells from the bone marrow.” PMID 32870250 ↗ Dec 20207“Mavorixafor (X4P-001) is an oral, selective, allosteric CXCR4 inhibitor” PMID 33507454 ↗ Jan 2021 |
| Known as | AMD070 | “This study will test the safety and anti-HIV activity of eight different doses of the HIV entry inhibitor AMD11070 (also known as AMD070) in HIV infected patients.” NCT00089466 ↗ |
| Known as | AMD11070 | “AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who have developed resistance to or are unable to take...” NCT00063804 ↗ |
| Known as | Cxcr4 inhibitor x4p-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL518924 ↗ |
| Known as | X4P-001 | “Mavorixafor (X4P-001) is an oral, selective, allosteric CXCR4 inhibitor” PMID 33507454 ↗ Jan 2021 |
| Known as | Xolremdi | ChEMBL registry synonym — accepted as the source's own label CHEMBL518924 ↗ |
| Action | Inhibit | “AMD070 binds to the chemokine receptor CXCR4, inhibiting membrane fusion and viral entry.” NCT00063804 ↗ |
| Modality | Small molecule | “Mavorixafor is an oral small molecule selective antagonist of the CXCR4 receptor that increases mobilization and trafficking of white blood cells from the bone marrow.” PMID 32870250 ↗ Dec 2020 |
| Route | Oral | “AMD070 is an oral CXCR4 antagonist” PMID 17452489 ↗ Apr 2007 |
| Target | CXCR4 | “AMD070 binds to the chemokine receptor CXCR4, inhibiting membrane fusion and viral entry.” NCT00063804 ↗ |